What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?

Scott A. McDonald (Lead / Corresponding author), Hamish A. Innes, Peter C. Hayes, John F. Dillon, Peter R. Mills, David J. Goldberg, Stephen Barclay, Sam Allen, Ray Fox, Andrew Fraser, Nicholas Kennedy, Diptendu Bhattacharyya, Sharon J. Hutchinson

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    The global burden associated with hepatitis C virus (HCV) infection has prompted a scale-up of antiviral therapy. Hitherto, no data existed on the impact of scaling-up on the characteristics of treated populations or on sustained viral response (SVR) rates. We assessed the country-wide scale-up of antiviral therapy in Scotland, a country which nationally monitors uptake of and response to HCV treatment METHODS: Data for patients initiated on combined pegylated interferon and ribavirin therapy at 13 specialist HCV clinics in 2001-2010 were extracted from the Scottish HCV Clinical Database (n=3895). Patient characteristics included age, genotype, PWID (people who inject drugs) status, prison referral, and diagnosed cirrhosis. Temporal trends in covariates and adjusted effects on SVR were examined via mixed-effects regression.
    Original languageEnglish
    Pages (from-to)262-268
    Number of pages7
    JournalJournal of Hepatology
    Volume62
    Issue number2
    DOIs
    Publication statusPublished - Feb 2015

    Keywords

    • Antiviral therapy
    • Hepatitis C virus
    • Pegylated interferon
    • Sustained viral response

    ASJC Scopus subject areas

    • Hepatology

    Fingerprint

    Dive into the research topics of 'What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?'. Together they form a unique fingerprint.

    Cite this